scholarly journals Modified Endoscopic Ultrasound Needle to Obtain Histological Core Tissue Samples: A Retrospective Analysis

2020 ◽  
Vol 53 (4) ◽  
pp. 471-479 ◽  
Author(s):  
Munish Ashat ◽  
Kaartik Soota ◽  
Jagpal S. Klair ◽  
Sarika Gupta ◽  
Chris Jensen ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Endoscopic Ultrasound ◽  
Tissue Samples ◽  
Core Tissue

scholarly journals Mo1331 RETROSPECTIVE ANALYSIS OF A MODIFIED ENDOSCOPIC ULTRASOUND NEEDLE TO OBTAIN HISTOLOGICAL TISSUE SAMPLES

2018 ◽  
Vol 87 (6) ◽  
pp. AB448-AB449
Author(s):  
Kaartik Soota ◽  
Jagpal S. Klair ◽  
Sarika Gupta ◽  
Arvind R. Murali ◽  
Chris Jensen ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Endoscopic Ultrasound ◽  
Tissue Samples

scholarly journals Pathologic evaluation of a new endoscopic ultrasound needle designed to obtain core tissue samples: A pilot study

2016 ◽  
Vol 5 (3) ◽  
pp. 178 ◽  
Author(s):  
DouglasG Adler ◽  
Benjamin Witt ◽  
Barbara Chadwick ◽  
Jason Wells ◽  
LindaJo Taylor ◽  
...  
Keyword(s):  
Pilot Study ◽  
Endoscopic Ultrasound ◽  
Tissue Samples ◽  
Pathologic Evaluation ◽  
Core Tissue

scholarly journals IS THE NEW PROCORE 20G DOUBLE FORWARD-BEVEL NEEDLE CAPABLE TO OBTAIN BETTER HISTOLOGICAL SAMPLES BY ENDOSCOPIC ULTRASOUND FOR DIAGNOSING SOLID PANCREATIC LESIONS?

2020 ◽  
Vol 33 (4) ◽  
Author(s):  
José Celso ARDENGH ◽  
Vitor Ottoboni BRUNALDI ◽  
Mariângela Ottoboni BRUNALDI ◽  
Alberto Facuri GASPAR ◽  
Jorge Resende LOPES-JÚNIOR ◽  
...  
Keyword(s):  
Endoscopic Ultrasound ◽  
Fine Needle Biopsy ◽  
Needle Aspiration ◽  
Technical Success ◽  
Tissue Samples ◽  
Fine Needle ◽  
Biopsy Methods ◽  
Sensitivity Specificity ◽  
Adequate Tissue

ABSTRACT Background: It is important to obtain representative histological samples of solid biliopancreatic lesions without a clear indication for resection. The role of new needles in such task is yet to be determined. Aim: To compare performance assessment between 20G double fine needle biopsy (FNB) and conventional 22G fine needle aspiration (FNA) needles for endoscopic ultrasound (EUS)-guided biopsy. Methods: This prospective study examined 20 patients who underwent the random puncture of solid pancreatic lesions with both needles and the analysis of tissue samples by a single pathologist. Results: The ProCore 20G FNB needle provided more adequate tissue samples (16 vs. 9, p=0.039) with better cellularity quantitative scores (11 vs. 5, p=0.002) and larger diameter of the histological sample (1.51±1.3 mm vs. 0.94±0.55 mm, p=0.032) than the 22G needle. The technical success, puncture difficulty, and sample bleeding were similar between groups. The sensitivity, specificity, and diagnostic accuracy were 88.9%, 100%, and 90% and 77.8%, 100%, and 78.9% for the 20G and 22G needles, respectively. Conclusions: The samples obtained with the ProCore 20G FNB showed better histological parameters; although there was no difference in the diagnostic performance between the two needles, these findings may improve pathologist performance.

Molecular profiling (MP)-selected therapy for the treatment of patients with advanced pancreaticobiliary cancer (PBC).

2013 ◽  
Vol 31 (4_suppl) ◽  
pp. 195-195
Author(s):  
Ron Epelbaum ◽  
Einat Shacham-Shmueli ◽  
Ravit Geva ◽  
Ayala Hubert
Keyword(s):  
Retrospective Analysis ◽  
Null Hypothesis ◽  
Impact Analysis ◽  
Treatment Decision ◽  
Treatment Selection ◽  
Outcome Analysis ◽  
Sequencing Analysis ◽  
Tissue Samples ◽  
Treatment Regimens ◽  
Guided Therapy

195 Background: For patients (pts) with advanced PBC who are able to pursue additional therapy, treatment selection is often empiric and clinical benefits are usually modest. Our goal was to study clinical outcomes of MP-guided treatment in advanced PBC. Methods: This retrospective analysis included pts with advanced PBC whose tissue samples underwent MP (IHC, microarray [MA], and sequencing analyses) using Target Now (Caris Life Sciences, Irving, TX). These pts received ≥1 lines of therapy for advanced PBC before their treatment was guided by MP. The MP-guided therapy was considered to have clinical benefit if the TTP ratio between the longest TTP on MP-guided therapy and the TTP on the last therapy pre-MP was ≥1.3. Results: Out of 20 pts included in the analysis, 16 had advanced cancer of the pancreas. Median age was 59 yrs (range: 30-81), 85% were male, and 60% had PS of 1. Pts had 1-4 treatment regimens (median: 1) prior to MP. MP identified 1-7 (median: 4) actionable targets per pt. The most commonly identified targets by IHC were: negative or low TS (80%), high TOPO1 (70%), negative or low ERCC1 (52%), and high SPARC (40%). In all 14 pts that had MA results, multiple actionable targets were identified. Of 14 pts with KRAS sequencing analysis, 10 pts (71%) had mutations. Post-MP, pts had 1-4 (median: 1) treatment regimens, most commonly FOLFIRI/XELIRI, FOLFOX/XELOX, capecitabine, and nab-paclitaxel. The total number of regimens post-MP was 33, of which 29 were evaluable for decision impact analysis. In 24 (83%) of cases, treatment decision was modified due to the MP results. Out of the 20 pts, 4 received ≤1 cycle of MP-guided therapy during rapidly progressing disease and were excluded from the clinical outcome analysis. Of the 16 evaluable pts, 6 (37.5%) had a TTP ratio of ≥1.3 (one-sided exact binomial test vs a null hypothesis of ≤15% with TTP ratio ≥1.3, P=0.0056; therefore the null hypothesis is rejected). Conclusions: In our retrospective analysis of a small, yet well-defined, cohort of pts with advanced PBC, MP often influenced treatment decisions and over a third of pts experienced a longer TTP (compared to the last regimen pre-MP), highlighting the promise in MP for treatment selection.

Sign in / Sign up

Export Citation Format

Share Document